Comment on ‘Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study’

被引：0
|
作者：
Matthew Dankner
April A. N. Rose
机构：
[1] McGill University,Goodman Cancer Research Centre
[2] McGill University,Department of Medicine
[3] University of Toronto,Department of Medicine, Division of Medical Oncology
来源：
British Journal of Cancer | 2018年 / 118卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1276 / 1277
页数：1
相关论文
共 50 条
  • [21] EGFR gene copy number as a predictive biomarker for the treatment of metastatic colorectal cancer with anti-EGFR monoclonal antibodies: a meta-analysis
    Yang, Zu-Yao
    Shen, Wei-Xi
    Hu, Xue-Feng
    Zheng, Da-Yong
    Wu, Xin-Yin
    Huang, Ya-Fang
    Chen, Jin-Zhang
    Mao, Chen
    Tang, Jin-Ling
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2012, 5
  • [22] BRAF V600E and survival benefit of anti-EGFR monoclonal antibody (mAb) therapy for metastatic colorectal cancer (mCRC): A meta-analysis.
    Sorich, Michael
    Rowland, Andrew
    Dias, Mafalda
    McKinnon, Ross Allan
    Kichenadasse, Ganessan
    Wiese, Michael
    Karapetis, Christos Stelios
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [23] CEA dynamics for predicting response after anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer
    Kang, Sora
    Kim, Sun Young
    Hong, Yong Sang
    Kim, Tae Won
    Choi, Ki Eun
    Kim, Min Jung
    Kim, Jeong Eun
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [24] Beyond KRAS:Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer
    Alfonso De Stefano
    Chiara Carlomagno
    World Journal of Gastroenterology, 2014, (29) : 9732 - 9743
  • [25] Beyond KRAS: Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer
    De Stefano, Alfonso
    Carlomagno, Chiara
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (29) : 9732 - 9743
  • [26] Review article: panitumumab - a fully human anti-EGFR monoclonal antibody for treatment of metastatic colorectal cancer
    Peeters, M.
    Balfour, J.
    Arnold, D.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2008, 28 (03) : 269 - 281
  • [27] CEA dynamics for predicting response after anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer
    Sora Kang
    Sun Young Kim
    Yong Sang Hong
    Tae Won Kim
    Ki Eun Choi
    Min Jung Kim
    Jeong Eun Kim
    Scientific Reports, 13
  • [28] RAS mutations as markers of resistance for colorectal cancer patients treated with the anti-EGFR monoclonal antibody panitumumab
    Oliner, K.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S7 - S8
  • [29] EGFR gene copy number as a predictive biomarker for resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer treatment:a meta-analysis
    Wei-Dong Shen
    Hong-Lin Chen
    Peng-Fei Liu
    Chinese Journal of Cancer Research, 2014, 26 (01) : 59 - 71
  • [30] EGFR gene copy number as a predictive biomarker for resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer treatment: a meta-analysis
    Shen, Wei-Dong
    Chen, Hong-Lin
    Liu, Peng-Fei
    CHINESE JOURNAL OF CANCER RESEARCH, 2014, 26 (01) : 59 - 71
12345